Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Vertex Pharmaceuticals Incorporated
Type
Corporation
Traded as NASDAQ: VRTX
Industry Pharmaceuticals & Biotherapeutics)
Founded 1989
Headquarters Boston, Massachusetts
Key people
  • Jeffrey Leiden, M.D., Ph.D., Chair, President and CEO
  • Stuart A. Arbuckle, Executive Vice President and Chief Commercial Officer
  • Kenneth L. Horton, Executive Vice President and Chief Legal Officer
  • Lisa Kelly-Croswell, Senior Vice President, Human Resources
  • Peter Mueller, Ph.D., Executive Vice President, Global Research and Development, and Chief Scientific Officer
  • Megan Pace, Senior Vice President, Corporate Communications
  • Amit K. Sachdev, Senior Vice President, Corporate Affairs and Public Policy
  • Ian F. Smith, Executive Vice President and Chief Financial Officer
Products Product Pipeline]
Revenue Increase US$1.4 billion (2011)
Website www.vrtx.com

Vertex Pharmaceuticals is an American Pharmaceutical company based in Boston, Massachusetts.

"We are aware of the financial complexities of the huge expenses for R & D with respect to the small number of patients or the market system that enables these advances to become reality. Yet -- notwithstanding all your patient support programs -- it is at best unseemly for Vertex to charge our patients’ insurance plans (including strapped state medical assistance plans), $294,000 annually for two pills a day (a 10-fold increase in a typical patient's total drug costs). This action could appear to be leveraging pain and suffering into huge financial gain for speculators, some of whom were your top executives who reportedly made millions of dollars in a single day (Boston Globe, May 29)."

Investment goal date:
Dividends reinvested
Vertex Pharmaceuticals Incorporated VRTX report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-04-27
--
--
Q4 2017
2018-02-07
--
--
Q3 2017
2017-10-25
0.5300
-0.4100
Q2 2017
2017-07-26
0.3900
0.0700
Q1 2017
2017-04-27
0.4100
0.9900
Q4 2016
2017-01-25
0.3500
0.1300
Q3 2016
2016-10-25
0.1600
-0.1600
Q2 2016
2016-07-27
0.2400
-0.2600
Q1 2016
2016-04-27
0.0900
-0.1700
Q4 2015
2016-01-27
0.1700
-0.3000
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
AMERIPRISE FINANCIAL INC
8238201
BlackRock Fund Advisors
6818014
BlackRock Group LTD
2967665
BlackRock Inc.
19246380
BlackRock Institutional Trust Company, N.A.
6532503
Capital World Investors
17900933
Clearbridge Investments, LLC
8754618
FMR LLC
18864648
GOLDMAN SACHS GROUP INC
4098306
JPMORGAN CHASE & CO
9361376
PRICE T ROWE ASSOCIATES INC /MD/
22978643
STATE STREET CORP
12013178
Vanguard Group, Inc
16474890
WADDELL & REED FINANCIAL INC
3634003
WELLINGTON MANAGEMENT CO LLP
17766033
Major Shareholders
Name Relationship
Total Shares
Holding stocks
BOGER JOSHUA S
0.1200% (284088)
VRTX /
SMITH IAN F
0.0200% (40888)
ACOR / INFI / OPHT / VRTX /
SACHS BRUCE I
0.0100% (26339)
VRTX /
LEIDEN JEFFREY M
0.1100% (257392)
DGX / VRTX /
MUELLER PETER
0.0600% (143517)
VRTX /
Sachdev Amit
0.0200% (50710)
VRTX /
Silva Paul M
0.0100% (16634)
VRTX /
Connolly Thomas
0.0100% (34375)
VRTX /
ALTSHULER DAVID
0.0400% (106011)
VRTX /
Horton Kenneth L
0.0300% (72053)
VRTX /
Pace Megan E
0.0200% (43350)
VRTX /
Arbuckle Stuart A
0.0200% (41952)
CERU / VRTX /
Chodakewitz Jeffrey
0.0200% (54424)
TTPH / VRTX /
% ()